Plasma Levels of Tumor Necrosis Factor and Its Receptors in Hodgkin's Disease
Author Information
Author(s): K Warzochal, J Bienvenu, P Ribeirol, I Moullet, C Dumontet, EM Neidhardt-Berard, B Coiffier, G Salles
Primary Institution: Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon and Universite Claude Bernard
Hypothesis
The study aims to assess the use of plasma measurement of tumor necrosis factor (TNF) and its soluble receptors for prognostic risk assignment in Hodgkin's disease patients.
Conclusion
Elevated plasma levels of TNF and its soluble receptors correlate with adverse clinical features and predict poorer outcomes in Hodgkin's disease patients.
Supporting Evidence
- Plasma levels of TNF, p55, and p75 were higher in Hodgkin's disease patients than in healthy controls.
- Elevated plasma levels of TNF, p55, and p75 were associated with several adverse prognostic factors.
- Patients with elevated TNF levels had a lower incidence of complete response to therapy.
- Elevated levels predicted shorter free-from-progression survival and overall survival.
Takeaway
Doctors measured certain proteins in the blood of patients with Hodgkin's disease to see if they could tell how sick the patients were and how well they would respond to treatment.
Methodology
A prospective study measuring plasma levels of TNF, p55, and p75 in 61 patients with Hodgkin's disease and comparing them to healthy controls.
Limitations
The study had a limited number of patients and a relatively short follow-up period.
Participant Demographics
The study included 61 patients (23 women and 38 men) with a median age of 37 years.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website